CWP
CPRX

Concord Wealth Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Concord Wealth Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$23 – 311
2025
Q4 		$23 Hold
1
– – ﹤0.01% 839
2025
Q3 		$20 Hold
1
– – ﹤0.01% 824
2025
Q2 		$22 Hold
1
– – ﹤0.01% 853
2025
Q1 		$24 Hold
1
– – ﹤0.01% 803
2024
Q4 		$21 Hold
1
– – ﹤0.01% 916
2024
Q3 		$20 Hold
1
– – ﹤0.01% 950
2024
Q2 		$15 Hold
1
– – ﹤0.01% 830
2024
Q1 		$16 Buy
+1
New +$15 ﹤0.01% 846

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Concord Wealth Partners's CPRX Position: Q1 2026 in Review

Concord Wealth Partners sold out of Catalyst Pharmaceutical (CPRX) in Q1 2026, closing a stake of 1 share — an estimated $23 sold.

Concord Wealth Partners first reported a position in CPRX in Q1 2024 and held it in 8 quarters. The position peaked at $24 in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Concord Wealth Partners reported no remaining Catalyst Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Concord Wealth Partners sold 1 Catalyst Pharmaceutical share in Q1 2026, an estimated $23.
  • Concord Wealth Partners first reported a position in Catalyst Pharmaceutical in Q1 2024 and held it in 8 quarters.
  • Concord Wealth Partners's Catalyst Pharmaceutical position peaked at $24 in Q1 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Concord Wealth Partners's 13F filing for Q1 2026, filed 1 May 2026.